Prevalence of Low Bone Mass and Vitamin D Deficiency in ß-Thalassemia Major.

Hemoglobin

PubMedID: 24762040

Tzoulis P, Ang AL, Shah FT, Berovic M, Prescott E, Jones R, Barnard M. Prevalence of Low Bone Mass and Vitamin D Deficiency in ß-Thalassemia Major. Hemoglobin. 2014;.
Abstract Low bone mass, a major cause of morbidity in patients with ß-thalassemia major (ß-TM), is multifactorial. There is lack of data about the current prevalence of low bone mass in patients with ß-TM. The aims of this study are to examine the current prevalence of low bone mass in ß-TM patients and the association between demographic characteristics, markers of iron overload, endocrinopathies, glycemic status and bone mineral density (BMD) as well as to study the 25-OH-vitamin D status of the patients and its relationship with BMD. Our institution serves the largest cohort of ß-TM patients in the UK. From 99 patients (49 males, 50 females) with a mean?±?standard deviation (SD) age of 36?±?9 years, 55.5% had low BMD for their age as defined by Z-score BMD <-2.0 either at the lumbar spine (43.9%) or at the hip (25.5%). The only statistically significant association on the multivariate analysis was between hypogonadism and low BMD at the lumbar spine. In our study, 29.9% of patients had vitamin D deficiency, 65.7% had vitamin D insufficiency and 12.4% had optimal levels. No association between vitamin D status and low bone mass was found. Our study demonstrated a much lower prevalence of low bone mass in adults with ß-TM compared to previous studies. Further studies are needed to examine whether this suggests a widespread improvement across patients with ß-TM possibly due to advances in therapeutics. Most patients had suboptimal 25-OH-vitamin D levels, but no association between vitamin D status and bone mass was demonstrated.